Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02216838 · ClinicalTrials.gov registry record · Phase 4
Treatment of Facial Flushing With Botulinum Toxin A Injections
A Phase 4 study of Facial Flushing, sponsored by Northwestern University.
- Active
- Registry status
- Phase 4
- Development phase
- 16
- Enrollment target
- 1
- Study location
NCT02216838 is a Phase 4 study of Facial Flushing that is active but no longer recruiting, run by Northwestern University. The registered enrollment target is 16 participants. The trial reports 1 study location across 1 state.
The verdict
NCT02216838, a Phase 4 study of Facial Flushing, is active but no longer recruiting, sponsored by Northwestern University.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 4
- Development phase
- 16 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to find out if botulinum toxin A (botox®) can be used to treat facial flushing. This study is a pilot study designed to determine feasibility of these procedures.
Conditions Studied
Interventions
- DRUG botulinum toxin A
- OTHER Saline Control
Study Locations (1)
Illinois
- Northwestern University Feinberg School of Medicine, Department of Dermatology - Chicago
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 16 participants |
| Start Date | 2014-08 |
| Est. Completion | 2025-12 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02216838
The ClinicalTrials.gov registry entry for NCT02216838 describes a study currently listed as active not recruiting, categorized as Phase 4. The registered enrollment target is 16 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Northwestern University, which has 1,209 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Facial Flushing appearing as the primary indexed condition, and to 2 interventions - of which botulinum toxin A is the first listed.
NCT02216838 reports 1 study location spanning 1 distinct geographic area - top geographies include Illinois.
Frequently Asked Questions
What is clinical trial NCT02216838 about?
NCT02216838 is a clinical study titled "Treatment of Facial Flushing With Botulinum Toxin A Injections". The purpose of this study is to find out if botulinum toxin A (botox®) can be used to treat facial flushing. This study is a pilot study designed to determine feasibility of these procedures.
What is the current status of trial NCT02216838?
This trial is currently active not recruiting. It is a Phase 4 study. The enrollment target is 16 participants. The study started on 2014-08. Estimated completion is 2025-12.
What conditions does trial NCT02216838 study?
This clinical trial studies the following conditions: Facial Flushing.
What interventions are being tested in trial NCT02216838?
The interventions under investigation include: botulinum toxin A (DRUG), Saline Control (OTHER).
Who is sponsoring clinical trial NCT02216838?
This trial is sponsored by Northwestern University, which has 1,209 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02216838 being conducted?
This trial has 1 study location across Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.